Novo Nordisk A/S (NVO) Reports Positive Results From First Phase 3 Trial With Long-Acting Factor IX for Treatment of Hemophilia B
5/17/2013
More...
|
Merck KGaA (MKGAF.PK) Doesn't Rule Out Pursuing Lung-Cancer Vaccine
5/17/2013
More...
|
Pearl Therapeutics Presents Dose-Ranging, Efficacy and Safety Results of PT003 as well as Components, PT001 and PT005 at American Thoracic Society Meeting
5/17/2013
More...
|
Sanofi (France) (SAN.PA) Plans to File JAK2 Inhibitor After Positive Phase III
5/17/2013
More...
|
Experimental Gilead Sciences, Inc. (GILD) Drug Effective in Early-Stage Leukemia Trial
5/16/2013
More...
|
Roche (RHHBY) Banks on New Drug Data to Defend Cancer Business
5/16/2013
More...
|
AstraZeneca PLC (AZN) Advances Three Cancer Drugs Into Late-Stage Trials
5/16/2013
More...
|
Genentech (RHHBY) Cancer Antibody, Son of Rituxan, Nails Pivotal Study
5/16/2013
More...
|
Transgenomic, Inc. (TBIO) Announces Global Availability of CRC RAScan™ Mutation Detection Test for Use in Patients With Metastatic Colorectal Cancer to Help Identify Appropriate Treatment
5/16/2013
More...
|
Forest Laboratories, Inc. (FRX) to Present Data from Cariprazine and Levomilnacipran Phase 3 Trials at American Psychiatric Association Annual Meeting
5/16/2013
More...
|
Northwest Biotherapeutics (NWBT) Initiates Phase III DCVax®-L Brain Cancer Trial in Europe: King's College Hospital in the UK is First Site to Open
5/16/2013
More...
|
Amgen (AMGN) Release: New Analyses Identify Predictive Biomarkers for Vectibix® (Panitumumab) in Patients With Metastatic Colorectal Cancer
5/16/2013
More...
|
Sanofi (France) (SAN.PA) and Regeneron Pharmaceuticals, Inc. (REGN) Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
5/15/2013
More...
|
Bayer HealthCare Pharmaceuticals (BAYA.F) Initiates Phase III Trial of Stivarga® (regorafenib) Tablets in Patients with Advanced Liver Cancer
5/15/2013
More...
|
Rib-X Pharmaceuticals, Inc. Initiates Delafloxacin Global Phase 3 Clinical Trial in Patients With Acute Bacterial Skin and Skin Structure Infections
5/14/2013
More...
|
Pearl Therapeutics Initiates PT003 Phase 3 Program for the Treatment of Individuals with Moderate-to-Severe COPD
5/14/2013
More...
|
Nuvilex's Dr. Gerald Crabtree Discusses Upcoming Phase III Cancer Trials, Fast Track and Orphan Drug Status
5/13/2013
More...
|
Medivir AB (MVIRb.F): FDA Grants Priority Review to Simeprevir for Combination Treatment of Genotype 1 Chronic Hepatitis C
5/13/2013
More...
|
BioAlliance Pharma Announces DSMB Second Positive Recommendation to Continue its Phase III Clinical Trial With Livatag® in Primary Liver Cancer
5/13/2013
More...
|
Relypsa, Inc. Completes Patient Enrollment in Pivotal Phase 3 Program for the Treatment of Hyperkalemia
5/13/2013
More...
|
Medivir AB (MVIRb.F) Release: FDA Grants Priority Review to Simeprevir for Combination Treatment of Genotype 1 Chronic Hepatitis C
5/13/2013
More...
|
Amgen (AMGN) Late-Stage Trial of Colon Cancer Drug Meets Goal
5/10/2013
More...
|
InSite Vision (ISV) Initiates Confirmatory Phase 3 Clinical Study of BromSite™ for the Reduction of Inflammation and Pain After Cataract Surgery
5/10/2013
More...
|
Failure of Baxter International, Inc. (BAX)'s Trial Another Blow to Alzheimer's Treatment
5/9/2013
More...
|
Onconova Therapeutics Inc. Completes Enrollment in ONTIME Pivotal Phase 3 Study of Rigosertib in Patients With High-risk Myelodysplastic Syndromes
5/9/2013
More...
|
Actelion Ltd. (ALIOF.PK) Gets Go-Ahead to Continue New Drug Trial
5/8/2013
More...
|
Alimera Sciences (ALIM) Announces First Patient Treated With Commercially Available ILUVIEN®
5/8/2013
More...
|
PAION AG Release: Recruitment of Phase II/III Study With Short-Acting Anaesthetic/Sedative Remimazolam (Ono's Development Code: ONO-2745) in Japan is Completed
5/8/2013
More...
|
FDA Grants Fast Track Designation for Cubist Pharmaceuticals, Inc. (CBST)’s Late-Stage Antibiotic Candidate
5/7/2013
More...
|
Celgene Corporation (CELG) Release: Apremilast Achieves Statistical Significance for the Primary and Major Secondary Endpoints in Fourth Pivotal Phase III Study (PALACE 4) of Patients With Psoriatic Arthritis
5/7/2013
More...
|
Data on Agile Therapeutics, Inc.' Low-Dose Contraceptive Patch (AG200-15) Presented at American College of Obstetricians and Gynecologist Annual Clinical Meeting
5/7/2013
More...
|
Array BioPharma, Inc. (ARRY) Announces Global Phase 3 Trial Evaluating MEK162 in Patients With Low-Grade Serous Ovarian Cancer
5/7/2013
More...
|
Gilead Sciences, Inc. (GILD)'s HCV Drugs Shine in Trials
5/6/2013
More...
|
AbbVie (ABBV)'s Investigational HCV Regimen Receives Breakthrough Therapy Designation
5/6/2013
More...
|
AbbVie (ABBV)'s Investigational HCV Regimen Receives Breakthrough Therapy Designation From the FDA
5/6/2013
More...
|
AMAG Pharmaceuticals, Inc. (AMAG) Release: Ferumoxytol Results in Significant Hemoglobin Increases in Adult Iron Deficiency Anemia Patients With Abnormal Uterine Bleeding Who Had Failed or Could Not Tolerate Oral Iron Therapy
5/6/2013
More...
|
Cardium Therapeutics, Inc. (CXM) Announces Generx Publication in Molecular Therapy
5/2/2013
More...
|
AcelRx Pharmaceuticals (ACRX) Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting
5/2/2013
More...
|
FDA Staff Says AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) (AVEO) Kidney Cancer Drug May Need More Study
5/1/2013
More...
|
Lantheus Medical Imaging to Proceed With Flurpiridaz F 18 Phase 3 Clinical Program Based on Interim Analysis of Data From First Phase 3 Study
5/1/2013
More...
|
Celsion Corporation (CLN) Announces ThermoDox® HEAT Study Findings to be Reviewed at the 9th Annual World Conference on Interventional Oncology (WCIO) in New York City on May 16, 2013
5/1/2013
More...
|
Intercept Pharmaceuticals Announces Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis Presented at EASL
4/30/2013
More...
|
FDA Gives "Breakthrough" Designation to Merck & Co., Inc. (MRK) Drug
4/29/2013
More...
|
Pfizer Inc. (PFE) Phase 3 Study of Prevenar 13 Meets Primary, Secondary Objectives
4/29/2013
More...
|
Basilea Pharmaceutica (BSLN.SW) Reports Presentation of New Data on Anti-Infective Drug Candidates Addressing Drug Resistance
4/29/2013
More...
|
Durata Therapeutics, Inc. (DRTX) Release: New Data Demonstrating In Vitro Potency of Dalbavancin Against Bacterial Pathogens Presented at the 23rd Annual ECCMID Meeting
4/29/2013
More...
|
Derma Sciences, Inc. (DSCI) Begins Screening Patients in Second Phase 3 Trial With DSC127 for Healing Diabetic Foot Ulcers
4/26/2013
More...
|
Ampio Pharmaceuticals, Inc. (AMPE) Completes Enrollment in Run-In SPRING Study of Ampion in Osteoarthritis of the Knee
4/25/2013
More...
|
Active Biotech AB (BTPC) and Ipsen (IPN.PA) Update the Analysis Plan for the 10TASQ10 Trial Evaluating Tasquinimod in the Treatment of Prostate Cancer
4/25/2013
More...
|
Pharm-Olam International Ltd. Completes Phase 3 Ophthalmology Study
4/25/2013
More...
|
XBiotech Enrolls First Patient in Phase III Pivotal Trial of Xilonix™
4/25/2013
More...
|
Bristol-Myers Squibb Company (BMY) Oral Hepatitis C Regimen Looks Competitive: Study
4/24/2013
More...
|
Data From Phase 3 Studies of Gilead Sciences, Inc. (GILD)'s Sofosbuvir for Hepatitis C in the Forefront
4/23/2013
More...
|
Drug Therapy Offers High Cure Rate for Two Hepatitis C Subtypes, Weill Cornell Medical College Study
4/23/2013
More...
|
Medivir AB (MVIRb.F) Release: New Data From Simeprevir Phase III Studies Quest 1 and 2 in Hepatitis C Patients Will be Presented at EASL 23-28 April in Amsterdam
4/23/2013
More...
|
Boehringer Ingelheim Pharmaceuticals, Inc.'s Faldaprevir-Based Treatment Regimen Achieved Viral Cure in up to 80 Percent of Patients with Hepatitis C in Phase 3 Pivotal Trial
4/23/2013
More...
|
Janssen R&D Ireland Release: Findings From Two Phase 3 Studies of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
4/23/2013
More...
|
Astellas Pharma Inc. (YPH.BE), GlaxoSmithKline (GSK) Vie to Make "High Altitude" Anemia Pill
4/22/2013
More...
|
SCM Pharma Limited Supports Clinical Scale-Up for Varisolve®
4/22/2013
More...
|
ADial Pharmaceuticals Announces Agreement With FDA for Phase III Trial of AD04 for Alcohol Use Disorder in Patients of Targeted Genotypes
4/19/2013
More...
|
Pharmacyclics, Inc. (PCYC) Completes Enrollment of First Phase III Ibrutinib CLL Study - RESONATE™ and Announces Completion of Enrollment of Phase II Ibrutinib MCL Study - SPARK
4/19/2013
More...
|
Romark Laboratories, L.C. Initiates Phase 3 Trial of New Influenza Drug
4/18/2013
More...
|
Teva Pharmaceutical Industries Limited (TEVA) Presented New Data From Phase III Clinical Trial of Milprosa™ (Progesterone) Vaginal Ring at the 61st Annual Meeting of the Pacific Coast Reproductive Society
4/17/2013
More...
|
Northwest Biotherapeutics (NWBT)'s Phase III Trial With DCVax®-L for Brain Cancer "Adopted" as a National Priority Trial in UK
4/16/2013
More...
|
Eli Lilly and Company (LLY) Announces Positive Results of Phase III Trials of Dulaglutide in Type 2 Diabetes
4/16/2013
More...
|
Bayer HealthCare Pharmaceuticals (BAYA.F) Initiates Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551T) in Mechanically Ventilated Patients With Gram-Negative Pneumonia
4/16/2013
More...
|
BHR Pharma, LLC Announces 1,000th Enrolled Patient in SyNAPSe® Trial
4/16/2013
More...
|
Forest Laboratories, Inc. (FRX) and Almirall Report Positive COPD Drug Data
4/16/2013
More...
|
GTX Corp's Phase III Clinical Studies of Enobosarm (GTx-024) to Continue as Planned Following Planned Safety Review
4/15/2013
More...
|
Pfizer Inc. (PFE)'s Palbociclib Gets FDA Breakthrough Label
4/12/2013
More...
|
Iroko Pharmaceuticals's Submicron NSAIDs Demonstrate Efficacy at Lower Doses in Studies in Patients With Acute and Chronic Pain
4/12/2013
More...
|
Navidea Biopharmaceuticals (NAVB)'s Presentation of Top-Line Interim Analysis of Lymphoseek® Head and Neck Phase 3 Trial Selected for Investigator Award
4/12/2013
More...
|
Elorac, Inc. Announces FDA Fast Track Designation for Novel Topical Treatment for Pruritus in Cutaneous T-cell Lymphoma (CTCL)
4/12/2013
More...
|
Pharmacyclics, Inc. (PCYC) Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
4/11/2013
More...
|
Lundbeck Inc. (LUN.CO) Announces Positive Results for Brintellix™ (Vortioxetine) in Adult Patients With Major Depression and Inadequate Response to SSRI or SNRI Therapy
4/10/2013
More...
|
XOMA Corporation (XOMA) Announces Clinical Study Investigating Gevokizumab in Patients With Non-Infectious Anterior Scleritis Has Opened for Enrollment at the National Eye Institute
4/10/2013
More...
|
EyeGate Pharma's EGP-437 Matches the Standard-of-Care's Response Rate in Phase III Study in Patients With Anterior Uveitis
4/9/2013
More...
|
Johnson & Johnson (JNJ), Pharmacyclics, Inc. (PCYC) Gets New Breakthrough-Therapy Designation for Ibrutinib
4/8/2013
More...
|
Kythera Biopharmaceuticals Announces Positive Interim Results From Open-Label P3 Study of ATX-101
4/8/2013
More...
|
AstraZeneca PLC (AZN)'s Arthritis Pill Disappoints Again
4/8/2013
More...
|
InDex Pharmaceuticals AB Completes Patient Recruitment in P3 Ulcerative Colitis Study With Kappaproct
4/8/2013
More...
|
Lundbeck Inc. (LUN.CO) Presents New Data on Selincro From Three Phase III Studies That Consistently Show a Significant Reduction in Alcohol Consumption in Alcohol Dependent Patients With High Risk Drinking Level
4/8/2013
More...
|
Amarin Corporation PLC (AMRN) Announces New Clinical Data Showing Significant Reductions in Apolipoprotein C-III Levels in MARINE and ANCHOR Studies of Vascepa®
4/8/2013
More...
|
Millennium: The Takeda Oncology Company Release: Meta-Analysis of VELCADE® (bortezomib)-Based Induction Therapy Followed by Stem-Cell Transplantation Showed Significantly Greater Response and Longer Progression-Free and Overall Survival in Patients With Multiple Myeloma
4/8/2013
More...
|
Navidea Biopharmaceuticals (NAVB) Reports Positive Top-Line Results From Interim Analysis of Lymphoseek
4/4/2013
More...
|
ProFibrix Completes Patient Enrolment in Pivotal Phase III With Fibrocaps™ and Reports Positive Feedback From Surgical Community
4/4/2013
More...
|
Vital Therapies, Inc. (VTI) Enrolls First Patient in VTI-208, a Controlled, Randomized Phase 3 Trial Evaluating the ELAD® System in Alcohol-Induced Liver Decompensation
4/4/2013
More...
|
Medivation, Inc. (MDVN) and Astellas Pharma Inc. (YPH.BE) Provide Update on PREVAIL
4/1/2013
More...
|
Adenosine Therapeutics Engages Needham & Company to Explore Strategic Options for Phase III Cardiac Stress Agent
4/1/2013
More...
|
Spectral Diagnostics (SDI.TO) Researchers Struggle to Develop New Treatments for Sepsis
4/1/2013
More...
|
Nuvilex Phase III Clinical Trials in Strong Hands With Dr. Gerald Crabtree
4/1/2013
More...
|
Effect of Genzyme Corporation (GENZ)'s LEMTRADA Maintained in Patients Beyond Two-Year Pivotal MS Studies
3/28/2013
More...
|
Anthera Pharmaceuticals, Inc. (ANTH) Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
3/28/2013
More...
|
Catalyst Pharmaceutical Partners, Inc. (CPRX) Announces Recommendation of Data Monitoring Committee for Pivotal Phase lll Clinical Trial for Firdapse(TM)
3/27/2013
More...
|
Gilead Sciences, Inc. (GILD) Announces Update on Phase 3 Study of Oral Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients
3/26/2013
More...
|
Synageva BioPharma (GEVA) Release: Late Onset LAL Deficiency (CESD) Literature Review Published in the Journal of Hepatology
3/26/2013
More...
|
Trius Therapeutics (TSRX)'s Tedizolid Meets Endpoint in Ph3
3/25/2013
More...
|
InSite Vision (ISV) Completes DOUBle Phase 3 Clinical Study of AzaSite Plus™ and DexaSite™ for the Treatment of Blepharitis
3/25/2013
More...
|
Sanofi (France) (SAN.PA)'s Lemtrada MS Drug Effective in Extension Trial
3/22/2013
More...
|
NeuroVive Pharmaceutical AB Release: 600th Heart Attack Patient Recruited into Phase III CicloMulsion® CIRCUS Trial
3/22/2013
More...
|
Intarcia Therapeutics, Inc. Enrolls First Patients in "Freedom" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
3/21/2013
More...
|
ACADIA Pharmaceuticals, Inc. (ACAD) Announces Presentation of Data From Its Pivotal Phase III Parkinson's Disease Psychosis Study With Pimavanserin at the American Academy of Neurology Annual Meeting
3/21/2013
More...
|
New Analysis Shows Novartis Pharmaceuticals Corporation (NVS) Drug Gilenya® Significantly Reduced Rate of Brain Volume Loss Across Three Large Phase III Studies
3/21/2013
More...
|
Navidea Biopharmaceuticals (NAVB) Release: Results of Lymphoseek® Phase 3 Clinical Trials in Breast Cancer Published in Annals of Surgical Oncology
3/21/2013
More...
|
Teva Pharmaceutical Industries Limited (TEVA) and Active Biotech AB (BTPC) See Positive Results From MS Study
3/21/2013
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB)'s Injectable MS Drug Cut Relapse Rate by 36 Pct
3/20/2013
More...
|
Amgen (AMGN)'s Melanoma Drug Shows Promise in Key Trial
3/20/2013
More...
|
InSite Vision (ISV) Announces Positive Phase 3 Results for BromSite™
3/20/2013
More...
|
FDA Reviewers Say Titan Pharmaceuticals (TTP) Drug Dose May be Insufficient
3/20/2013
More...
|
Adocia Announces Its Phase III Development Program for the Treatment of Diabetic Foot Ulcer
3/20/2013
More...
|
Adamas Pharmaceuticals Presents New Traumatic Brain Injury Data From Its Nurelin™ Program at American Academy of Neurology Conference
3/20/2013
More...
|
Boehringer Ingelheim Corporation and Eli Lilly and Company (LLY) Begin MARLINA Clinical Trial
3/19/2013
More...
|
Novo Nordisk A/S (NVO) Pleased With Obesity Trial Results
3/19/2013
More...
|
Acasti Pharma Presents Preliminary Data Moving Forward With Clinical Strategy
3/19/2013
More...
|
Trimel Pharmaceuticals P3 Shows Statistically Significant Improvement on Erectile Function and Mood
3/18/2013
More...
|
AOP Orphan Pharmaceuticals AG Release: Essential Thrombocythemia (ET) – Convincing Data of ANAHYDRET Study Now Published
3/18/2013
More...
|
Nymox Pharmaceutical (NYMX) Announces Presentation of NX-1207 Data at Annual Meeting of the European Association of Urology
3/18/2013
More...
|
Eli Lilly and Company (LLY) Release: New Study of Cialis® (tadalafil) Tablets Co-administered With Finasteride Meets Primary Endpoint in Men With Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia
3/18/2013
More...
|
R-Tech Ueno: Start of the Patient Enrollment of a Phase 3 Clinical Study of Unoprostone (Development Code UF-021) Ophthalmic Solution for the Treatment of Retinitis Pigmentosa
3/18/2013
More...
|
Santarus Inc. (SNTS) Announces Publication in Gut of Results From UCERIS (budesonide) European Pivotal Clinical Study
3/18/2013
More...
|
OphthaliX Inc. Announces the Completion of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study
3/18/2013
More...
|
Nuvilex Diabetes Studies Could Eliminate Need for Daily Insulin Requirements
3/18/2013
More...
|
Sinovac Biotech Ltd. (SVA) Vaccine for Hand, Foot and Mouth Disease Meets Study Goal
3/15/2013
More...
|
Marinomed Biotechnologie GmbH Release: Antiviral Nasal Spray - Data From Two Clinical Studies Prove Effectiveness of Marinomed's Antiviral Drug
3/15/2013
More...
|
AMAG Pharmaceuticals, Inc. (AMAG) Announces Positive Preliminary Results From an Extension Study Evaluating the Safety and Efficacy of Repeat Dosing With Ferumoxytol in Patients With Persistent or Recurring Iron Deficiency Anemia, Regardless of the Underlying Cause
3/15/2013
More...
|
BioAlliance Pharma Pursues the Development Plan of Its Loramyc® in Japan Through Its Partner Sosei
3/12/2013
More...
|
Sosei Group Corporation Announces Initiation of Phase III Study for SO-1105 for the Treatment of Oropharyngeal Candidiasis
3/12/2013
More...
|
Radius Completes Enrollment for Phase 3 Study of Bone-Building Osteoporosis Drug
3/12/2013
More...
|
Eisai Inc. (ESALF.PK) Slams German Decision on Fycompa; Takeda Pharmaceutical Co. Ltd. (TKPYY) Files Vedolizumab With European Medicines Agency
3/11/2013
More...
|
The Medicines Company (MDCO) Drug More Effective Than Plavix in Coronary Procedures
3/11/2013
More...
|
Teva Pharmaceutical Industries Limited (TEVA) Holds Its Breath During Third Phase 3 Trial
3/8/2013
More...
|
Bayer AG (BAY.F), Johnson & Johnson (JNJ) Eye Wider Use for Xarelto With New Trials
3/8/2013
More...
|
AlphaMed Release: Therapeutic Combination for HER2-Positive Breast Cancer Does Not Increase Cardiac Problems, but Cancer Patients' Heart Health Should be Monitored
3/8/2013
More...
|
Northwest Biotherapeutics (NWBT) Provides Guidance on Phase III Trial Enrollment Timing: Completion Expected to be Faster or More Efficient Than Relevant Comparison Trials
3/7/2013
More...
|
AcelRx Pharmaceuticals (ACRX) Pain Treatment Meets Late-Stage Study Goal
3/6/2013
More...
|
Celgene Corporation (CELG)'s Apremilast Succeeds in Phase 3 Psoriasis Trial
3/5/2013
More...
|
Positive Results for Kythera Biopharmaceuticals and Bayer AG (BAY.F)'s ATX-101 in the Reduction of "Double Chin"
3/5/2013
More...
|
Pfizer Inc. (PFE) Presents Phase 3 Safety and Immunogenicity Data on Prevnar 13® in Adults With HIV
3/5/2013
More...
|
UCB, Inc. (UCBJF.PK) Had Positive Trial for Vimpat as Monotherapy
3/5/2013
More...
|
Teva Pharmaceutical Industries Limited (TEVA) Publishes Results From Milprosa Phase 3
3/4/2013
More...
|
Boehringer Ingelheim Pharmaceuticals, Inc. Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated With Faldaprevir
3/4/2013
More...
|
FDA Grants QIDP and Fast Track Designations for Cubist Pharmaceuticals, Inc. (CBST)'s Late-Stage Antibiotic Candidates
3/1/2013
More...
|
Anacor Pharmaceuticals, Inc. (ANAC) Reveals Positive Data From Second Phase-3 Trial of Tavaborole
3/1/2013
More...
|
Invaron Pharmaceuticals and the Center for Assisted Reproduction (CARE) Initiate Investigator Led Phase III Clinical Study on INVOcell(TM)
3/1/2013
More...
|
Boehringer Ingelheim Corporation Announces Initiation of Pivotal Trial Investigating Volasertib in Patients With Acute Myeloid Leukaemia
2/28/2013
More...
|
Alchemia Completes Enrolment in Pivotal Phase III HA-Irinotecan Trial of Metastatic Colorectal Cancer
2/28/2013
More...
|
Vertex Pharmaceuticals Incorporated (VRTX) Readies Late-Stage Cystic Fibrosis Drug Studies
2/27/2013
More...
|
Merck KGaA (MKGAF.PK) Drug Fails in Late-Stage Brain Cancer Trial
2/26/2013
More...
|
ANTISENSE PHARMA GmbH Announces Revised Development Path for Trabedersen
2/26/2013
More...
|
Durata Therapeutics, Inc. (DRTX) Sees Positive Results From Dalbavancin Study
2/25/2013
More...
|
EMD Serono Reports Disappointing Results for Cancer Drug Test
2/25/2013
More...
|
CEL-SCI (CVM) Announces Initiation of New Sites for Multikine Phase III Clinical Study for Head and Neck Cancer in Taiwan
2/25/2013
More...
|
Novartis Pharmaceuticals Corporation (NVS) Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
2/25/2013
More...
|
Boehringer Ingelheim Corporation Drug Shows Benefits in New Asthma Trial
2/25/2013
More...
|
Repros Therapeutics Inc. (RPRX) Gets FDA Nod on Androxal Study
2/22/2013
More...
|
Pfizer Inc. (PFE) Says Lyrica Capsules CV Met Primary Endpoint in Phase 3 Study
2/21/2013
More...
|
Puma Biotechnology Reaches Deal With FDA on SPA for Phase III Trial of PB272
2/20/2013
More...
|
Gilead Sciences, Inc. (GILD) Sees Positive Results From Late-Stage Hepatitis C Treatment Study
2/19/2013
More...
|
Genzyme Corporation (GENZ) Touts Positive Ph3 Drug Data
2/19/2013
More...
|
Imprimis Pharmaceuticals (immy) Announces Successful Results From Its Pharmacokinetic Study for Its Impracor Topical NSAID
2/19/2013
More...
|
Isis Pharmaceuticals, Inc. (ISIS) Initates Phase 2/3 Study of ISIS-TTR Rx and Earns $7.5 Million Milestone Payment From GlaxoSmithKline
2/19/2013
More...
|
Regeneron Pharmaceuticals, Inc. (REGN) and Bayer HealthCare (BAY) Initiate Phase 3 Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Asia and Russia
2/19/2013
More...
|
Osiris Therapeutics, Inc. (OSIR) Receives Title of European Orphan Drug Designation for Prochymal®
2/19/2013
More...
|
Johnson & Johnson (JNJ)'s Partner Pharmacyclics, Inc. (PCYC) Blood Cancer Therapy a "Breakthrough"
2/15/2013
More...
|
FDAAdvisoryCommittee.com Grants Orphan Drug Status to Eisai Inc. (ESALF.PK)'s Lenvatinib
2/15/2013
More...
|
Amicus Therapeutics, Inc. (FOLD) Presents Additional 6-Month Results From Phase 3 Fabry Monotherapy Study at LDN World Symposium
2/15/2013
More...
|
Northwest Biotherapeutics (NWBT) Takes Next Steps in Moving Forward With Its Phase III Brain Cancer Trial in Europe
2/15/2013
More...
|
rEVO Biologics Release: ATryn Antithrombin (Recombinant) Prevents Venous Thromboembolic Events in Pregnant Patients With Hereditary Antithrombin Deficiency
2/15/2013
More...
|
Algeta: Further Sub-Analyses of ALSYMPCA Phase III Study Presented at 2013 Genitourinary Cancers Symposium
2/15/2013
More...
|
Astellas Pharma Inc. (YPH.BE) and AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) (AVEO) Report Positive Kidney Cancer Drug Trial Data
2/14/2013
More...
|
Optimer Pharmaceuticals, Inc. (OPTR) Release: New Analysis Shows Age Has a Significant Effect on Outcomes in Patients Being Treated for Clostridium Difficile Infection (CDI)
2/14/2013
More...
|
BHR Pharma, LLC Investigational Traumatic Brain Injury Treatment Receives European Medicines Agency Orphan Medicinal Product Designation
2/14/2013
More...
|
ZIOPHARM Oncology, Inc. (ZIOP.OB)'s Treatment for Soft Tissue Sarcoma Meets Study Goals
2/12/2013
More...
|
Ferring Pharmaceuticals to Highlight Phase 3 Data for Cervical Ripening Candidate at Society for Maternal-Fetal Medicine Annual Meeting
2/12/2013
More...
|
Synageva BioPharma (GEVA) Initiates Dosing in Phase 3 Trial of Sebelipase Alfa in Children and Adults Wth Late Onset LAL Deficiency
2/11/2013
More...
|
ADVENTRX Pharmaceuticals Inc. (ANX) Initiates Thorough QT/QTc Clinical Study Of ANX-188
2/11/2013
More...
|
RNL Bio Filed Phase II/III Clinical Trial with KFDA to Treat Cerebral Palsy Using Autologous Fat Derived Stem Cells
2/11/2013
More...
|
Pozen, Inc. (POZN) Presents Positive Phase 3 Results
2/8/2013
More...
|
Shire plc (SHPG) Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients With Epidermolysis Bullosa
2/8/2013
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB) Release: New Phase 3 Data Reinforce Long-Lasting Protection From Bleeding for Patients With Hemophilia A and B
2/8/2013
More...
|
ARCA biopharma Release: Unmet Medical Need in Treatment of Heart Failure Patients With Atrial Fibrillation Highlighted in Articles in Inaugural Issue of JACC: Heart Failure
2/7/2013
More...
|
Gilead Sciences, Inc. (GILD) Meets Main Goals of Two Phase III Studies; Company Moves Closer to First Hepatitis C Pill
2/6/2013
More...
|
BioSpecifics Technologies Corporation (BSTC) Announces Online Publication in The Journal of Urology of Results From the IMPRESS Trials of XIAFLEX® in Peyronie's Disease
2/5/2013
More...
|
Genentech (RHHBY) Says Blood Cancer Drug Met Stage One Goal
2/4/2013
More...
|
Rockwell Medical Technologies (RMTI) Iron Deficiency Drug Meets Trial Goal
2/4/2013
More...
|
Keryx Biopharmaceuticals (KERX) Falls on Questions About Zerenex Market Exclusivity
2/4/2013
More...
|
Auxilium Pharmaceuticals (AUXL) Announces IMPRESS Trials of XIALFEX® in Peyronie's Disease Were Published Online in the Journal of Urology
2/4/2013
More...
|
Celsion Corporation (CLN)'s Plummets on Phase 3 Liver Cancer Failure
2/1/2013
More...
|
Daiichi Sankyo, Inc. (4568.t) and ArQule, Inc. (ARQL) Enroll First Hepatocellular Carcinoma Patient Into Global Phase 3 Trial for Tivantinib
1/31/2013
More...
|
Cell Therapeutics, Inc. (CTIC) Announces Data Safety and Monitoring Board Recommendation to Continue the GOG-0212 Phase 3 Clinical Trial of OPAXIOTM as Maintenance Therapy in Ovarian Cancer
1/31/2013
More...
|
Anacor Pharmaceuticals, Inc. (ANAC) Falls on Positive But Disappointing Toenail Fungus Data
1/30/2013
More...
|
ARCA biopharma Release: New Adaptive Phase 3 Trial Planned for Gencaro™ in Atrial Fibrillation
1/30/2013
More...
|
ADVENTRX Pharmaceuticals Inc. (ANX) Initiates Pivotal Phase 3 Study of ANX-188
1/30/2013
More...
|
Keryx Biopharmaceuticals (KERX) Kidney Drug Meets Late-Stage Trial Goal
1/29/2013
More...
|
Charleston Laboratories, Inc. Begins Enrollment for CL-108 Phase 3 Clinical Trial
1/28/2013
More...
|
AlphaMed Release: Multinational Cooperation Necessary to Speed Clinical Trial Results
1/28/2013
More...
|
Amgen (AMGN) Announces Results From Phase 3 PAVES Study Evaluating Neulasta® (pegfilgrastim) in Patients With Colorectal Cancer
1/28/2013
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB) Says MS Drug Worked in Broad Study
1/25/2013
More...
|
Celgene (CELG)'s Abraxane Keeps Pancreatic Pts Alive an Extra Two Months in Trial
1/24/2013
More...
|
Gilead Sciences, Inc. (GILD) Initiates Phase 3 Clinical Program for Tenofovir Alafenamide, a Novel Low-Dose Prodrug for the Treatment of HIV
1/24/2013
More...
|